Summary
Erythroderma with complicated etiology is one of the severe skin diseases and has high mortality, of which the incidence was 0.5‰–1.5‰ in skin diseases. Erythrodermic psoriasis (EP) is the commonest type of erythroderma. In addition, there are drug-induced erythroderma, erythroderma secondary to preexisting dermatoses, malignancy-related erythroderma, and idiopathic erythroderma of unknown etiology. Erythroderma of different etiologies has various clinical manifestations, resulting in relevant curative effects and outcomes. In this article, we retrospectively investigated 205 erythroderma patients about clinical symptoms, auxiliary examination and treatments, and evaluated the efficacy and prognosis. There were 84 cases of EP among 205 patients, 10 cases of erythroderma caused by specific drugs, 77 cases of erythroderma secondary to preexisting dermatoses (excluding psoriasis), 7 cases of erythroderma patients suffering from malignancy and 27 cases with unknown causes. We concluded that the etiology of male patients in different age groups had significant difference. The incidence of EP was the highest among all types. The EP was commonly accompanied with hypoproteinemia, and changed into psoriasis vulgaris after treatment. Drug-induced erythroderma was commonly accompanied with fever, and mostly cured by systematic steroid therapy. For erythroderma secondary to preexisting dermatoses, the original dermatoses must be actively treated to achieve a satisfying prognosis. Erythroderma with malignancy or unknown causes had long-term duration, poor response to the treatment, and high potential to relapse. Therefore, clarifying the etiology, providing an appropiate and individual regimen, and regular follow-up are crucial for the successful treatment of erythroderma with unknown causes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mistry N, Gupta A, Alavi A, et al. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care, 2015,28 (5):228–236
Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol, 2010,62(4):655–662
Burton JL. Eczema, lichenification, prurigo and erythroderma[ M]/Champion RH. Textbook of Dermatology. 5th ed. Boston: Blackwell,1992:584–588
Akhyani M, Ghodsi ZS, Toosi S, et al. Erythroderma: a clinical study of 97 cases. BMC Dermatol, 2005,5:5
Salami TA, Enahoro Oziegbe O, Omeife H. Exfoliative dermatitis: patterns of clinical presentation in a tropical rural and suburban dermatology practice in Nigeria. Int J Dermatol, 2012,51(9):1086–1089
Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in The Netherlands. J Am Acad Dermatol, 2001,45(5):675–678
Zhang P, Chen HX, Duan YQ, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technol Med Sci, 2014,34(4):596–601
Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol, 2014,28(6):700–711
Vachatova S, Andrys C, Krejsek J, et al. Metabolic syndrome and selective inflammatory markers in psoriatic patients. J Immunol Res, 2016,2016:5380792
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002,106(25):3143–3421
Vadakayil AR, Dandekeri S, Kambil SM, et al. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J, 2015,6(5):322–325
Itani S, Arabi A, Harb D, et al. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol, 2016,55(4):390–395
Praveenkumar U, Ganguly S, Ray L, et al. Prevalence of metabolic syndrome in psoriasis patients and its relation to disease duration: A hospital based case-control study. J Clin Diagn Res, 2016,10(2):WC01–5
Thaçi D, Augustin M, Krutmann J, et al. Importance of basic therapy in psoriasis. J Dtsch Dermatol Ges, 2015,13 (5):415–418
Feely MA, Smith BL, Weinberg JM. Novel psoriasis therapies and patient outcomes, part 1: topical medications. Cutis, 2015,95(3):164–168
Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol, 2004, 140(3):366
Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci, 2001,941:1–11
Torres-Camacho P, Tirado-Sanchez A, Ponce-Olivera RM. Erythroderma: clinical and laboratory follow up of 66 Mexican patients. Indian J Dermatol Venereol Leprol, 2009,75(5):522–523
Boehncke WH, Schön MP. Psoriasis. Lancet, 2015,386 (9997):983–994
Tan GF, Kong YL, Tan AS, et al. Causes and features of erythroderma. Ann Acad Med Singapore, 2014,43(8):391–394
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was partly supported by the National Natural Science Foundation of China (No. 81673057 and No. 81502735).
Rights and permissions
About this article
Cite this article
Zhang, P., Chen, Hx., Xing, Jj. et al. Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010–2015. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 37, 563–567 (2017). https://doi.org/10.1007/s11596-017-1773-1
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-017-1773-1